Kaiser Daily HIV/AIDS Report Highlights Recently Published Clinical Infectious Diseases Studies

The following summarizes studies recently published in the journal Clinical Infectious Diseases.

• "Use of Efavirenz Is Not Associated With a Higher Risk of Depressive Disorders: A Substudy of the Randomized Clinical Trial ALIZE-ANRS 099," Clinical Infectious Diseases: Valerie Journot of the Institut International de la Sante et de la Recherche Medicale in Bordeaux, France, and colleagues looked at the effect of the antiretroviral drug efavirenz on depression. The study finds that incidence of depression was not linked to use of the drug (Journot et al., Clinical Infectious Diseases, 6/15).
  

• "Optimizing Treatment for HIV-Infected South African Women Exposed to Single-Dose Nevirapine: Balancing Efficacy and Cost," Clinical Infectious Diseases: Charles Holmes of Massachusetts General Hospital and colleagues compared the antiretroviral drug nevirapine with the drug lopinavir-ritonavir for cost-effectiveness and life-expectancy in HIV-positive South African women. The researchers found that a regimen that begins with the more costly lopinavir-ritonavir followed by nevirapine increased life-expectancy and was cost-effective in South Africa (Holmes et al., Clinical Infectious Diseases, 6/15).